References on the Administration of Chemotherapeutic Agents Using ALZET® Osmotic Pumps

1. Actinomycin

P1379 Kanje,M., Lundborg,G., Edstrom,A. A new method for studies of the effects of locally applied drugs on peripheral nerve regeneration in vivo. Brain Research 1988; 439(--):116-121. >>> Actinomycin D; Cycloheximide; Mitomycin C; Vinblastine; Ringer's solution; CSF/CNS (sciatic nerve); rat; 2001; 2002; 3, 4, 6 days; mp connected to silicone cuff; functionality of mp verified in vivo with dye; tissue perfusion.

top of page

2. Angiostatin

8331 Dirkx, A.E.M., Egbrink, M.G.A.O., Castermans, K., van der Schaft, D.W.J., Thijssen, V.L.J.L., Dings, R.P.M., Kwee, L., Mayo, K.H., Wagstaff, J., Steege, J.C.A.B., Griffioen, A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB Journal 2006; 20(-6-):621-630. >>> Anginex; endostatin; BSA; angiostatin; Saline; SC; Mice; Controls received mp w/ BSA or no treatment; dose-response (fig.5); cancer (melanoma, colon carcinoma); animal info (C57BL/6).

6784 Vogten, J.M., Drixler, T.A., te Velde, E.A., Schipper, M.E., van Vroonhoven, T.J.M.V., Voest, E.E., Rinkes, I.H.M.B. Angiostatin inhibits experimental liver fibrosis in mice. International Journal of Colorectal Disease 2004; 19(-4-):387-394. >>> Angiostatin; PBS; SC; Mice; 2002; Controls received mp w/ vehicle; no stress (see pg. 389).

top of page

3. Ara-C

16132 Hamilton, L. K., Dufresne, M., Joppe, S. E., Petryszyn, S., Aumont, A., Calon, F., Barnabe-Heider, F., Furtos, A., Parent, M., Chaurand, P., Fernandes, K. J. Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease. Cell Stem Cell 2015; 17(-4-):397-411. >>> Ara-C; Oleic Acid; AB142089; Ara-C; Oleic Acid; AB142089; CSF/CNS (cerebroventricular); mice; 1007D; 1004; Controls received mp w/ vehicle; animal info: 2-month-old WT or 3xTg-AD mice; functionality of mp verified by Analysis of brain sections by IMS; cancer; dose-response (pg 407); neurodegenerative (NSC impairment); enzyme inhibitor (SCD-1 inhibitor– AB142089); Dose: 500 mM Oleic Acid; 10mM C12 Oleic Acid conjugated to vehicle; 10mM C13 Oleic Acid conjugated to vehicle; 2% AraC; 40 mM SCD-1 inhibitor.

16127 Ghanbari, A., Esmaeilpour, T., Bahmanpour, S., Golmohammadi, M. G., Sharififar, S., Azari, H. Depletion of neural stem cells from the subventricular zone of adult mouse brain using cytosine b-Arabinofuranoside. Brain Behav 2015; 5(-11-):e00404. >>> Ara-C; Saline; CSF/CNS (right lateral ventricle); Mice; 1007D; Controls received sham operation and mp w/ vehicle; animal info: Five-week-old male C57-BL6 mice; pumps replaced once after 7 days; ALZET brain infusion kit 3 used; good methods (pg 2); post op. care (0.5 mg/kg buprenorphine every 12 h for 48 hours); cyanoacrylate adhesive (Loctite 454); delayed delivery (6-12 hours); Dose: 2% Ara-C in Saline; Brain coordinates; Paxinos mouse brain Atlas: Anterior-Posterior (AP): _0. 2, Medial-Lateral (ML): +0. 9 from the bregma point and Dorsal-Ventral: +2.7 from the top of skull.

15775 H. JIA,, F. FRANCOIS,, J. BOURIEN,, M. EYBALIN,, R. V. LLOYD, T. R. VAN DE WATER,, J.-L. PUEL, F. VENAIL. PREVENTION OF TRAUMA-INDUCED COCHLEAR FIBROSIS USING INTRACOCHLEAR APPLICATION OF ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE DRUGS. neuroscience 2016; 316(--):261-278. >>> Dexamethasone; Ara-C; Perilymph, artificial; Ear (cochlea); Rat; 2001; Controls received mp w/ vehicle; animal info (Wistar, adult); animal info (Wistar, adult); stability verified by (incubation in 37C saline for 7 days see pg 268); one cochlea received vehicle only, while other recieved drug;.

14735 Ferent, J., Cochard, L., Faure, H., Taddei, M., Hahn, H., Ruat, M., Traiffort, E., Ruat, M. Genetic Activation of Hedgehog Signaling Unbalances the Rate of Neural Stem Cell Renewal by Increasing Symmetric Divisions. STEM CELL REPORTS 2014; 3(--):312-323. >>> Ara-C; Saline; CSF/CNS; Mice; Animal info (Ptc -/-, 8-12 weeks old); brain tissue distribution;.

14645 Sun, D., Daniels, T.E., Rolfe, A., Waters, M., Hamm, R., Sun, D. Inhibition of Injury-Induced Cell Proliferation in the Dentate Gyrus of the Hippocampus Impairs Spontaneous Cognitive Recovery after Traumatic Brain Injury. Journal of Neurotrauma 2015; 32(--):495-505. >>> Ara-C; CSF, artificial; CSF/CNS; Rat; 1007D; Control animals received mp w/ vehicle; ALZET Brain infusion kit 2 used; animal info (male, 3-4 mo old, Sprague Dawley).

top of page

4. Azacytidine

11378 Guo, J.J.U., Ma, D.K.K., Mo, H., Ball, M.P., Jang, M.H., Bonaguidi, M.A., Balazer, J.A., Eaves, H.L., Xie, B., Ford, E., Zhang, K., Ming, G.L., Gao, Y., Song, H.J. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nature Neuroscience 2011; 14(-10-):1345-U172. >>> RG108; azacytidine, 5-; CSF/CNS; Mice; 1003D; Controls received mp w/ saline; animal info (wt, Gadd45b KO, 8-10 wks old, male); enzyme inhibitor (DNA methyltransferases).

604 Zaharko, D.S., Covey, J.M., Kelley, J.A. Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor. Invest. New Drugs 1985; 3(--):35-41. >>> Azacytidine, 5,6-dihydro-5-; PBS; SC; mice; 2001; cancer chemotherapy; pumps primed in PBS for 24 hr. prior to implant; solubility limit of DHAC is 820mg/ml at room temp; comparison with previous injec.´ infusion data.

top of page

5. Bevacizumab

15133 Wang, W.J., Sivakumar, W., Torres, S., Jhaveri, N., Vaikari, V.P., Gong, A., Howard, A., Golden, E.B., Louie, S.G., Schoenthal, A.H., Hofman, F.M., Chen, T.C., Chen, T.C. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurgical Focus 2015; 38(--):U112-U119. >>> Bevacizumab; Saline; CSF/CNS (intratumoral); Mice (nude); 1004; Controls received mp w/ vehicle; animal info (athymic, nu/nu); ALZET brain infusion kit used; cancer (glioma); immunology;"Bevacizumab was delivered into the tumor using chronic pump-mediated delivery, defined as“convection-enhanced delivery” or CED. This CED method was used because it has the advantage of achieving the desirable drug concentration in the microenvironment of the glioma while avoiding the use of high initial doses."pg 2;.

15045 Morishita, K., Takemura, G., Tsujimoto, A., Kanamori, H., Okada, H., Chousa, M., Ushimaru, S., Mikami, A., Kawamura, I., Takeyama, T., Kawaguchi, T., Watanabe, T., Goto, K., Morishita, M., Ushikoshi, H., Kawasaki, M., Ogura, S., Minatoguchi, S., Takemura, G. Postinfarction Cardiac Remodeling Proceeds Normally in Granulocyte Colony-Stimulating Factor Knockout Mice. AMERICAN JOURNAL OF PATHOLOGY 2015; 185(--):1899-1911. >>> Bevacizumab; Saline; SC; Mice; 1002; Controls received mp w/ vehicle; animal info (G-CSF-KO, 10-12 weeks); cardiovascular;.

top of page

6. Bleomycin

15788 Rapha€el Lemaire, Timothy Burwell, Hong Sun, Tracy Delaney, Julie Bakken, Lily Cheng, Marlon C. Rebelatto, Meggan Czapiga, Isabelle de-Mendez, Anthony J. Coyle, Ronald Herbst, Robert Lafyatis, Jane Connor. Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor. ARTHRITIS&RHEUMATOLOGY 2016; 68(-2-):473-483. >>> Bleomycin; SC; Mice; animal info (C57Bl6, 6-10 weeks old); Dose (100 mg/kg);.

14484 Wu, W.T., Ichihara, G., Hashimoto, N., Hasegawa, Y., Hayashi, Y., Tada-Oikawa, S., Suzuki, Y., Chang, J., Kato, M., Alessandro-Gabazza, C.N., Gabazza, E.C., Ichihara, S., Ichihara, G. Synergistic Effect of Bolus Exposure to Zinc Oxide Nanoparticles on Bleomycin-Induced Secretion of Pro-Fibrotic Cytokines without Lasting Fibrotic Changes in Murine Lungs. International Journal of Molecular Sciences 2015; 16(--):660-676. >>> Bleomycin sulfate; Saline; SC; Mice; 2001; Controls received mp w/ vehicle; animal info (female, C57BL6J, 9 weeks old, 19-22g); cardiovascular;.

14363 Reese, C., Lee, R., Bonner, M., Perry, B., Heywood, J., Silver, R.M., Tourkina, E., Visconti, R.P., Hoffman, S., Hoffman, S. Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry. FRONTIERS IN PHARMACOLOGY 2014; 5(--):U1-U13. >>> Bleomycin; caveolin-1 scaffolding domain peptide;; Saline; DMSO; water; SC; Mice; 1007D; 2002; Controls received mp w/ vehicle; animal info (male, CD1, 10 weeks old); 10% DMSO used; immunology; bleomycin had saline vehicle; CSD had DMSO and water vehicle; caveolin-1 scaffolding domain peptide aka CSD; bleomycin pumps removed after days 10-12 and replaced with CSD pumps;.

14275 Liang, M.R., Lv, J.Y., Zou, L.L., Yang, W., Xiong, Y.L., Chen, X.J., Guan, M., He, R., Zou, H.J., He, R. A modified murine model of systemic sclerosis: bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis. LABORATORY INVESTIGATION 2015; 95(--):342-350. >>> Bleomycin; Saline; SC; Mice; 2004; Controls received mp w/ vehicle; animal info (C57BL6, 6-8 weeks old); no stress (see pg. 344); immunology;.

14265 Lee, R., Reese, C., Bonner, M., Tourkina, E., Hajdu, Z., Riemer, E.C., Silver, R.M., Visconti, R.P., Hoffman, S., Hoffman, S. Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY 2014; 306(--):L736-L748. >>> Bleomycin; Saline; SC; Mice; 1007D; Controls received mp w/ vehicle; animal info (male, CD1, 10 weeks old); comparison of injection vs mp; immunology;"the pump model provides additional major benefits compared with the direct model. Much less weight loss and mortality is observed in the pump model than in the direct model. Therefore, besides the fact that the pump model is more humane, it also benefits the researcher because it allows the number of surviving animals in treatment groups to be accurately predicted, thereby making analyses of biochemical and cell biological parameters at the end of an experiment more meaningful."pg L747; pumps removed after 10 days; human scleroderma interstitital lung disease model;.

14262 Lee, R., Perry, B., Heywood, J., Reese, C., Bonner, M., Hatfield, C.M., Silver, R.M., Visconti, R.P., Hoffman, S., Tourkina, E., Tourkina, E. Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. FRONTIERS IN PHARMACOLOGY 2014; 5(--):U1-U14. >>> Bleomycin; Saline; SC; Mice; 1007D; Controls received mp w/ vehicle; animal info (male, CD1, 10 weeks old); comparison of injection vs mp;"Recently, we found that systemic bleomycin delivery using subcutaneously implanted osmotic minipumps can produce a very useful mouse model for SSc in which fibrosis is observed in the skin, lungs, and a variety of other internal organs"pg 2;"We recently compared two methods of delivering bleomycin [Direct Model (directly into the lungs) and Pump Model (systemic delivery using implanted osmotic minipumps)]and found that the lung disease induced in the Pump Model was distinct from the disease induced in the Direct Model and more similar to the lung disease observed in SSc patients"pg 4; pumps removed after 10 days;.

top of page

7. CDDP

6660 Ohtsukasa, S., Okabe, S., Yamashita, H., Iwai, T., Sugihara, K. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. Journal of Cancer Research and Clinical Oncology 2003; 129(-12-):719-726. >>> CDDP; fluorouracil, 5-; IP; Mice; 1007D; Controls received mp w/ saline; pumps replaced after 7 days; cancer (colorectal); CDDP (Cisdiamminedichloroplatinum II); is a chemotherapeutic agent.

top of page

8. Carboplatin

13699 Yang, W.L., Barth, R.F., Huo, T.Y., Nakkula, R.J., Weldon, M., Gupta, N., Agius, L., Grecula, J.C. Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors. Radiation Oncology 2014; 9(-;-):U20-U28. >>> Carboplatin; CSF/CNS; Rat; 2001; animal info (male, Fischer, 200-220 g, F98 glioma bearing); cancer (glioma); comparison of mp with convection enhanced delivery (CED).

13236 Huo, T.Y., Barth, R.F., Yang, W.L., Nakkula, R.J., Koynova, R., Tenchov, B., Chaudhury, A.R., Agius, L., Boulikas, T., Elleaume, H., Lee, R.J. Preparation, Biodistribution and Neurotoxicity of Liposomal Cisplatin following Convection Enhanced Delivery in Normal and F98 Glioma Bearing Rats. PLoS One 2012; 7(-11-):U98-U107. >>> Carboplatin; Rat; Animal info (F98 Glioma bearing rats); cancer (brain); infusion of carboplatin via alzet minipump along with radiotherapy produced a 2.5 to 3.6 fold increase in the mean survival time of F98 glioma bearing rats with a subset of cured animals;.

13164 Zhidkov, N., De Souza, R., Ghassemi, A.H., Allen, C., Piquette-Miller, M. Continuous Intraperitoneal Carboplatin Delivery for the Treatment of Late-Stage Ovarian Cancer. MOLECULAR PHARMACEUTICS 2013; 10(-9-):3315-3322. >>> Carboplatin; PBS; IP; Mice (SCID); 1002; Controls received mp w/ saline; toxicology; animal info (6-8 week old female SCID); comparison of bolus injection vs mp; cancer (ovarian).

12637 Bobyk, L., Edouard, M., Deman, P., Rousseau, J., Adam, J.F., Ravanat, J.L., Esteve, F., Balosso, J., Barth, R.F., Elleaume, H. Intracerebral delivery of Carboplatin in combination with either 6 MV Photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma. JOURNAL OF EXPERIMENTAL&CLINICAL CANCER RESEARCH 2012; 31(-;-):U1-U7. >>> Carboplatin; Dextrose; CSF/CNS; Rat; 2001; Animal info (F98 glioma bearing); cancer; brain tissue distribution.

11686 Yang, W.L., Huo, T.Y., Barth, R.F., Gupta, N., Weldon, M., Grecula, J.C., Ross, B.D., Hoff, B.A., Chou, T.C., Rousseau, J., Elleaume, H. Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. Journal of Neuro-oncology 2011; 101(-3-):379-390. >>> Carboplatin; Saline, normal; CSF/CNS (striatum); Rat; 2001; ƤControls received mp w/ vehicle; animal info (Fischer, 220-240 g); cancer (glioma);"Prolonged infusion of carboplatin by means of Alzet osmotic pumps yielded the longest MST (mean survival time), and 2 of 5 rats were cured of their tumors."pg 388; 45]."It is noteworthy that in this study the brainstem was not damaged by direct infusion of 200 ul of carboplatin (0.5 mg/ml), and that there was no neurotoxicity until a lethal dose (dose (greater than/equal to) 1.0 mg/ml) was administered."pg 388.

10838 Iwasa, T., Okamoto, I., Takezawa, K., Yamanaka, K., Nakahara, T., Kita, A., Koutoku, H., Sasamata, M., Hatashita, E., Yamada, Y., Kuwata, K., Fukuoka, M., Nakagawa, K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer 2010; 103(-1-):36-42. >>> YM-155; cisplatin; carboplatin; DMSO; IV; Mice (nude); 1007D; Controls received mp w/ vehicle; animal info (male, nude, BALB/cAnNCrj-nu/nu, 5 weeks old); 0.1% DMSO used; cancer.

top of page

9. Cetuximab

12996 Talasila, K.M., Soentgerath, A., Euskirchen, P., Rosland, G.V., Wang, J., Huszthy, P.C., Prestegarden, L., Skaftnesmo, K.O., Sakariassen, P.O., Eskilsson, E., Stieber, D., Keunen, O., Brekka, N., Moen, I., Nigro, J.M., Vintermyr, O.K., Lund-Johansen, M., Niclou, S., Mork, S.J., Enger, P.O., Bjerkvig, R., Miletic, H. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathologica 2013; 125(-5-):683-698. >>> Cetuximab; CSF/CNS (intratumoral); Rat (nude); 2ML4; Control animals received mp w/ PBS; animal info (rnu/rnu Rowett); ALZET brain infusion kit 2 used; convection enhanced delivery (CED); tissue perfusion (intratumoral).

10081 Martens, T., Laabs, Y., Guenther, H.S., Kemming, D., Zhu, Z.P., Witte, L., Hagel, C., Westphal, M., Lamszus, K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clinical Cancer Research 2008; 14(-17-):5447-5458. >>> Cetuximab; CSF/CNS (intratumoral); Mice (nude); 2004; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (NMRI- nu/nu, 6-8 wks old); cetuximab is a monoclonal antibody against EGFR.

top of page

10. Cisplatin

10838 Iwasa, T., Okamoto, I., Takezawa, K., Yamanaka, K., Nakahara, T., Kita, A., Koutoku, H., Sasamata, M., Hatashita, E., Yamada, Y., Kuwata, K., Fukuoka, M., Nakagawa, K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer 2010; 103(-1-):36-42. >>> YM-155; cisplatin; carboplatin; DMSO; IV; Mice (nude); 1007D; Controls received mp w/ vehicle; animal info (male, nude, BALB/cAnNCrj-nu/nu, 5 weeks old); 0.1% DMSO used; cancer.

9101 Chirino, Y.I., Trujillo, J., Sanchez-Gonzalez, D.J., Martinez-Martinez, C.M., Cruz, C., Bobadilla, N.A., Pedraza-Chaverri, J. Selective iNOS inhibition reduces renal damage induced by cisplatin. TOXICOLOGY LETTERS 2008; 176(-1-):48-57. >>> 1400W; cisplatin; Saline; SC; Rat; 2001; Controls received mp w/ vehicle; enzyme inhibitor (iNOS); animal info (male, Wistar, 230-275g.).

top of page

11. Cyclophosphamide

10290 Mercapide, J., Rappa, G., Anzanello, F., King, J., Fodstad, O., Lorico, A. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. International Journal of Cancer 2010; 126(-5-):1206-1215. >>> Cyclophosphamide; CSF/CNS; Mice (nude); Controls received mp w/ sterile saline; animal info (6 wks old, female).

7984 Damber, J.E., Vallbo, C., Albertsson, P., Lennernaes, B., Norrby, K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemotherapy and Pharmacology 2006; 58(-3-):354-360. >>> Cyclophosphamide; paclitaxel; Saline; SC; Rat; 2ML1; Controls received mp w/ vehicle; cancer (AT-1 adenocarcinoma); animal info (adult, male, copenhagen);"Continuous/metronomic therapy may achieve a more pronounced anti-tumoural effect and significantly diminish the side effects compared with conventional bolus MTD-type chemotherapy."(p. 359).

top of page

12. Doxorubicin

12553 Knoell, R., Linke, W.A., Zou, P.J., Miocic, S., Kostin, S., Buyandelger, B., Ku, C.H., Neef, S., Bug, M., Schaefer, K., Knoell, G., Felkin, L.E., Wessels, J., Toischer, K., Hagn, F., Kessler, H., Didie, M., Quentin, T., Maier, L.S., Teucher, N., Unsoeld, B., Schmidt, A., Birks, E.J., Gunkel, S., Lang, P., Granzier, H., Zimmermann, W.H., Field, L.J., Faulkner, G., Dobbelstein, M., Barton, P.J.R., Sattler, M., Wilmanns, M., Chien, K.R. Telethonin Deficiency Is Associated With Maladaptation to Biomechanical Stress in the Mammalian Heart. Circulation Research 2011; 109(-7-):758-U153. >>> Doxorubicin; Mice; Animal info (telethonin KO, 26-38 wks old); infusion rate of 0.5 ul/hr.

9825 Loch, T., Vakhrusheva, O., Piotrowska, I., Ziolkowski, W., Ebelt, H., Braun, T., Bober, E. Different extent of cardiac malfunction and resistance to oxidative stress in heterozygous and homozygous manganese-dependent superoxide dismutase-mutant mice. Cardiovascular Research 2009; 82(-3-):448-457. >>> Doxorubicin; PBS; SC; Mice; 2002; Controls received mp w/vehicle; animal info (4.5 mo. old).

9175 Wenzel, P., Mueller, J., Zurmeyer, S., Schuhmacher, S., Schulz, E., Oelze, M., Pautz, A., Kawamoto, T., Wojnowski, L., Kleinert, H., Muenzel, T., Daiber, A. ALDH-2 deficiency increases cardiovascular oxidative stress - Evidence for indirect antioxidative properties. Biochemical and Biophysical Research Communications 2008; 367(-1-):137-143. >>> Nitroglycerin; acetaldehyde; doxorubicin; Ethanol; SC; IP; Mice; Controls received mp w/ vehicle; cardiovascular; animal info (10 wks old, male, ALDH-2 null); nitroglycerin also known as glycerol trinitrate, GTN;"chronic (in contrast to short term/acute) treatment with doxorubicin lead to a more pronounced increase in mitochondrial ROS formation and to a greater extent of endothelial as well as smooth muscle dysfunction"pg. 141.

top of page

13. Endostatin

13997 Lin, C.H.S., Chen, J., Ziman, B., Marshall, S., Maizel, J., Goligorsky, M.S., Goligorsky, M.S. Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy?. American Journal of Physiology-Heart and Circulatory Physiology 2014; 306(--):H1692-H1699. >>> Peptide, endostatin mP1; DMSO; PBS; SC; Mice; 2004; Controls received mp w/ vehicle; animal info (C57, 2 months old); 50% DMSO used; peptides; femoral artery ligation; cardiovascular;.

9024 Kurosaka, D., Yoshida, K., Yasuda, J., Yasuda, C., Noda, K., Furuya, K., Ukichi, T., Kingetsu, I., Joh, K., Yamaguchi, N., Saito, S., Yamada, A. The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 2007; 36(-6-):434-441. >>> Endostatin; PBS; IP; Mice; Controls received mp w/ vehicle; animal info (1J, 6 week);"compared with the once daily dosing regimen, the administration of endostatin by an osmotic pump achieved a similar arthritis-inhibiting effect at one-tenth of the dose...the administration method using osmotic pump is useful."pg. 434.

8583 Mulder, W.J.M., van der Schaft, D.W.J., Hautvast, P.A.I., Strijkers, G.J., Koning, G.A., Storm, G., Mayo, K.H., Griffioen, A.W., Nicolay, K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal 2007; 21(-2-):378-383. >>> Endostatin; anginex; SC; Mice; Controls received mp w/ saline; cancer (melanoma); peptides; MRI; animal info (C57BL/6, 6 weeks old); antiangiogenesis.

top of page

14. Etoposide

10115 Giraud, S., Bessette, B., Boda, C., Lalloue, F., Petit, D., Mathonnet, M., Jauberteau, M.O. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 30(--):273-281. >>> Fas ligand; etoposide; dexamethasone; CSF, artificial; CSF/CNS (intratumoral); Rat (nude); 1002; Tissue perfusion (tumor); functionality of mp verified by residual volume; cancer (glioblastoma); animal info (female 2 months old, 159 g.).

5341 Peng, D., Qian, C., Sun, Y., Barajas, M.A., Prieto, J. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno- associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol 2000; 32(-6-):975-985. >>> Etoposide; IP; Rat; Functionality of mp verified by measuring etoposide concentration in tumor tissue; cancer; etoposide (VP-16) is a chemotherapeutic agent.

top of page

15. Fluorouracil

11932 Atkinson, J.M., Shelat, A.A., Carcaboso, A.M., Kranenburg, T.A., Arnold, L.A., Boulos, N., Wright, K., Johnson, R.A., Poppleton, H., Mohankumar, K.M., Feau, C., Phoenix, T., Gibson, P., Zhu, L.Q., Tong, Y.A., Eden, C., Ellison, D.W., Priebe, W., Koul, D., Yung, W.K.A., Gajjar, A., Stewart, C.F., Guy, R.K., Gilbertson, R.J. An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. CANCER CELL 2011; 20(-3-):384-399. >>> Fluorouracil, 5-; SC; Mice (nude); 2001D; Animal info (CD-1, 8 wks old, 23-28 g); cancer.

11063 Tsukioka, S., Uchida, J., Tsujimoto, H., Nakagawa, F., Sugimoto, Y., Oka, T., Kiniwa, M. Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: Evidence from a xenograft model of folate-depleted mice. Molecular Medicine Reports 2009; 2(-3-):393-398. >>> Fluorouracil, 5-; Sailne, sterile; SC; Mice (nude); 2002; Animal info (BALB/cA-nu/nu, 4-5 wks old); cancer (colorectal);"oral S-1/LV therapy inhibited the growth of COL-1 tumors more effectively than the infusion of 5-FU/LV when administered at doses of similar toxicity"pg 397.

9731 Albertsson, P., Lennernaes, B., Norrby, K. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncologica 2009; 48(-3-):418-425. >>> Fluorouracil, 5-; NaCl; SC; Rat; 2ML2; Controls received mp w/ vehicle; no stress (see pg. 420); pumps primed;"No animal died during the surgical procedure or post surgical period"; angiogenesis;"The animals behaved normally and there were no signs of diarrhea or stomatitis."pg 240.

top of page

16. Gefitnib

11224 Agarwal, S, Sane, R, Gallardo, J.L., Ohlfest, J.R., Elmquist, W.F. Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux. Journal of Pharmacology and Experimental Therapeutics 2010; 334(-1-):147-155. >>> Gefitnib; DMSO; IP; Mice; 1003D; Animal info (wt, Mdr1a/b -/- Bcrp1 -/-, ); dose-response (Table 1); half-life (p.149)"1 hour in mice"; wound clips used; chemotherapeutic.

10669 Peng, S.C., Lai, Y.T., Huang, H.Y., Huang, H.D., Huang, Y.S. A novel role of CPEB3 in regulating EGFR gene transcription via association with Stat5b in neurons. NUCLEIC ACIDS RESEARCH 2010; 38(-21-):7446-7457. >>> Endothelial growth factor, recomb.; gefitnib; DMSO; CSF, artificial; BSA; CSF/CNS; Mice; 1004; Controls received mp w/ vehicle; animal info (8 wks old, male, C57BL/6J); behavioral testing (Morris water maze test); gefitinib is a chemotherapeutic.

top of page

17. Getfitnib

Q4435 Grisanti,L.A., Repas,A.A., Talarico,J.A., Gold,J.I., Carter,R.L., Koch,W.J., Tilley,D.G., Tilley,D.G. Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic beta-adrenergic receptor stimulation. American Journal of Physiology-Heart and Circulatory Physiology 2015; 308(--):H316-H330. >>> Isoproterenol; getfitnib; DMSO; PBS, sterile; Mice; 7 days; 14 days; Controls received mp w/ vehicle; animal info (male, C57BL6, 12 weeks old); cardiovascular;.

top of page

18. Imatinib

15110 Napier, R.J., Norris, B.A., Swimm, A., Giver, C.R., Harris, W.A.C., Laval, J., Napier, B.A., Patel, G., Crump, R., Peng, Z.H., Bornmann, W., Pulendran, B., Buller, R.M., Weiss, D.S., Tirouvanziam, R., Waller, E.K., Kalman, D., Napier, R.J. Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity. PLoS Pathogens 2015; 11(--):U1651-U1677. >>> Imatinib mesylate; Water; SC; Mice; 1007D; 2002; Controls received mp w/ vehicle; animal info (male, C57BL6, 6 weeks old); functionality of mp verified by serum levels; dose-response (pg.9); immunology;.

13743 Chu, J., Lauretti, E., Craige, C.P., Pratico, D., Pratico, D. Pharmacological Modulation of GSAP Reduces Amyloid-beta Levels and Tau Phosphorylation in a Mouse Model of Alzheimer's Disease with Plaques and Tangles. JOURNAL OF ALZHEIMERS DISEASE 2014; 41(--):729-737. >>> Imatinib; Cerebrospinal fluid, artificial; CSF/CNS (intrathecal); Mice (transgenic); 1007D; Controls received mp w/ vehicle; animal info (triple transgenic ABBP, PS1, P301L); neurodegenerative (Alzheimer's);"Since it is known that the drug does not penetrate the blood-brain barrier efficiently, it is possible that the contradictory results reflect this property of the drug. For this reason in the current study, we delivered Imatinib by means of implanted osmotic minipumps directly in the brains of the triple transgenic mice"pg 730; Imatinib aka STI571 akd Gleevec; used dental cement;.

12205 Launay, J.M., Herve, P., Callebert, J., Mallat, Z., Collet, C., Doly, S., Belmer, A., Diaz, S.L., Hatia, S., Cote, F., Humbert, M., Maroteaux, L. Serotonin 5-HT(2B) receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood 2012; 119(-7-):1772-1780. >>> Imatinib mesylate; Mice; Controls received mp w/ vehicle; animal info (5HT-2b -/-, adult, 7-9 wks old); imatinib mesylate also known as Gleevec or STI-571; hypoxia.

top of page

19. Marimastat

15034 Marshall, D.C., Lyman, S.K., McCauley, S., Kovalenko, M., Spangler, R., Liu, C., Lee, M., O'Sullivan, C., Barry-Hamilton, V., Ghermazien, H., Mikels-Vigdal, A., Garcia, C.A., Jorgensen, B., Velayo, A.C., Wang, R., Adamkewicz, J.I., Smith, V., Smith, V. Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One 2015; 10(--):U2689-U2714. >>> Marimastat; DMSO; water; SC; Rat; 2ML4; Controls received mp w/ vehicle; animal info (male, Lewis); 50% DMSO used; behavioral testing (resting posture, gait);.

12516 Mazurek, S.G.N., Li, J., Nabozny, G.H., Reinhart, G.A., Muthukumarana, A.C., Harrison, P.C., Fryer, R.M. Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors. Journal of Pharmacological and Toxicological Methods 2011; 64(-1-):89-96. >>> Marimastat; DMSO; water; SC; Rat; 2ML2; Controls received mp w/ vehicle; animal info (Sprague Dawley, male, 180-370); wound clips used; enzyme inhibitor (matrix metalloproteinase, MMP-13).

11746 Frant, J., Veerendhar, A., Chernilovsky, T., Nedvetzki, S., Vaksman, O., Hoffman, A., Breuer, E., Reich, R. Orally Active, Antimetastatic, Nontoxic Diphenyl Ether-Derived Carbamoylphosphonate Matrix Metalloproteinase Inhibitors. ChemMedChem 2011; 6(-8-):1471-1477. >>> Marimastat; Propylene glycol; DMSO; SC; Rat; 2ML2; animal info (male, Lewis, 150-180 g); 50% DMSO used.

top of page

20. Metacept

9830 Restall, C., Doherty, J., Bin Liu, H., Genovese, R., Paiman, L., Byron, K.A., Anderson, R.L., Dear, A.E. A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. International Journal of Cancer 2009; 125(-2-):483-487. >>> Metacept 1; DMSO; cremophor; saline; SC; Mice; Half-life (p.483) 20 min.; cancer (breast); animal info (female BALB/c); enzyme inhibitor (histone deacetylase); chemotherapeutic.

top of page

21. Metacept 1

P9572 Restall,C., Doherty,J., Bin Liu,H., Genovese,R., Paiman,L., Byron,K.A., Anderson,R.L., Dear,A.E. A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. International Journal of Cancer 2009; 125(-2-):483-487. >>> Metacept 1; DMSO; cremophor; saline; SC; Mice; 26 days; Half-life (p.483) 20 min.; cancer (breast); animal info (female BALB/c); enzyme inhibitor (histone deacetylase); chemotherapeutic.

top of page

22. Methotrexate

9684 Scholz, J., Abele, A., Marian, C., Haeussler, A., Herbert, T.A., Woolf, C.J., Tegeder, I. Low-dose methotrexate reduces peripheral nerve injury-evoked spinal microglial activation and neuropathic pain behavior in rats. Pain 2008; 138(-1-):130-142. >>> Methotrexate; dexamethasone; CSF, artificial; PBS; CSF/CNS (intrathecal); Rat; Controls received mp w/ vehicle; dose-response (fig. 7); comparison of IP injections vs. mp; enzyme inhibitor (dihydrofolate reductase); animal info (male, Sprague Dawley, 160-200 g., SNI); behavioral testing (paw withdrawal, mechanical allodynia, cold allodynia);"sustained intrathecal treatment may therefore suppress microglial activation much more efficiently than intermittent high-dose bolus injections."(p. 140).

7488 Lobo, E.D., Balthasar, J.P. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. Journal of Pharmaceutical Sciences 2005; 94(-9-):1957-1964. >>> Methotrexate; IP; Mice; 1003D; Controls received ip bolus saline injection; dose-response (fig. 3); cancer (peritoneal sarcoma); toxicology; mp primed overnight in 37 degrees saline.

top of page

23. Mitomycin

P1993 Fu,K.K., Lam,K.N. Early and late effects of mitomycin C and continuous low-dose-rate irradiation on the mouse skin and soft tissues of the leg. Int.J.Radiat.Oncol.Biol.Phys. 1991; 21(--):1523-1528. >>> Mitomycin C; Saline; IP; mice; no duration posted; cancer.

P1874 Lu,X., Richardson,P.M. Inflammation near the nerve cell body enhances axonal regeneration. J.Neurosci. 1991; 11(-4-):972-978. >>> Mitomycin C; CSF/CNS (spinal cord, intrathecal); rat; no duration posted; no comment posted.

P1379 Kanje,M., Lundborg,G., Edstrom,A. A new method for studies of the effects of locally applied drugs on peripheral nerve regeneration in vivo. Brain Research 1988; 439(--):116-121. >>> Actinomycin D; Cycloheximide; Mitomycin C; Vinblastine; Ringer's solution; CSF/CNS (sciatic nerve); rat; 2001; 2002; 3, 4, 6 days; mp connected to silicone cuff; functionality of mp verified in vivo with dye; tissue perfusion.

P1302 Kawano,S., Yano,S., Sakamoto,S., Ogata,J. Effect of continuous intravesical infusion of low-concentrated mitomycin-C on bladder carcinogenesis in rats treated with N-butyl-N-4-hydroxybutyl-nitrosamine. J.Urol. 1988; 139(--):1343-1346. >>> Mitomycin C; bladder; rat; 2ML2; 2 weeks; mp connected to catheter; dose-response (graph, text); comparison of twice weekly injections vs. mp infusion; functionality of mp verified by urine levels; cancer/immunology; tissue perfusion.

P0818 Murphy,W.M., Blatnik,A.F., Shelton,T.B., Soloway,M.S. Carcinogenesis in mammalian urothelium: changes induced by non-carcinogenic substances and chronic indwelling catheters. J.Urol. 1986; 135(-4-):840-844. >>> Mitomycin; Water; bladder; rat; 1 year and 3 weeks; pump replaced periodically; mp connected to bladder via catheter; tumors induced by infusion of water or agent; lesions reversible over time; long-term study; cancer; controls received surgery only; mps cultured upon removal; tissue perfusion.

P0422 Akaza,H., Murphy,W.M., Soloway,M.S. Bladder cancer induced by noncarcinogenic substances. J.Urol. 1984; 131(--):153-155. >>> Formalin, neutral buffered; Water; Cisplatin; Mitomycin C; Saline; Saline; bladder; rat; 2002; 1, 2, and 3 weeks; cancer; comparison of agents carcinogenic effects; empty mp used in one exp.; mp connected to catheter in bladder; confusion over length of pumping time-states 18-22 days for 14 day pump; tissue perfusion.

top of page

24. Other Chemotherapeutic

Q2729 Roberts,K.G., Morin,R.D., Zhang,J.H., Hirst,M., Zhao,Y.J., Su,X.P., Chen,S.C., Payne-Turner,D., Churchman,M.L., Harvey,R.C., Chen,X., Kasap,C., Yan,C.H., Becksfort,J., Finney,R.P., Teachey,D.T., Maude,S.L., Tse,K., Moore,R., Jones,S., Mungall,K., Birol,I., Edmonson,M.N., Hu,Y., Buetow,K.E., Chen,I.M., Carroll,W.L., Wei,L., Ma,J., Kleppe,M., Levine,R.L., Garcia-Manero,G., Larsen,E., Shah,N.P., Devidas,M., Reaman,G., Smith,M., Paugh,S.W., Evans,W.E., Grupp,S.A., Jeha,S., Pui,C.H., Gerhard,D.S., Downing,J.R., Willman,C.L., Loh,M., Hunger,S.P., Marra,M.A., Mullighan,C.G. Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. CANCER CELL 2012; 22(-2-):153-166. >>> Ruxolitinib; Dimethylacetamide; propylene glycol; SC; Mice; 4 weeks; Control animals received mp w/ vehicle; animal info (BCR-JAK2); enzyme inhibitor (JAK2, janus kinase 2); cancer; chemotherapeutic.

Q2576 Agarwal,S., Manchanda,P., Vogelbaum,M.A., Ohlfest,J.R., Elmquist,W.F. Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma. Drug Metabolism and Disposition 2013; 41(-1-):33-39. >>> Erlotinib; DMSO; IP; Mice; 1003D; 48 hours; Animal info (Mdr1ab -/-, Bcrp1 -/-, 8-10 wks old); wound clips used; half-life ("approximately 1 hour") pg 34; cancer (glioma); "Erlotinib half-life in mice has been reported to be approximately 1 hour (Marchetti et al., 2008), so an infusion lasting 48 hours was considered to be sufficient to attain steady state in both the brain and plasma." pg 34; chemotherapeutic.

Q2575 Li,L., Agarwal,S., Elmquist,W.F. Brain Efflux Index To Investigate the Influence of Active Efflux on Brain Distribution of Pemetrexed and Methotrexate. Drug Metabolism and Disposition 2013; 41(-3-):659-667. >>> Pemetrexed; IP; Mice; 1003D; 72 hours; animal info (C57BL/6, male, Bcrp 1 -/-); post op. care (ibuprofen in the drinking water); pemetrexed is an antifolate; chemotherapeutic;.

Q2314 Maude,S.L., Tasian,S.K., Vincent,T., Hall,J.W., Sheen,C., Roberts,K.G., Seif,A.E., Barrett,D.M., Chen,I.M., Collins,J.R., Mullighan,C.G., Hunger,S.P., Harvey,R.C., Willman,C.L., Fridman,J.S., Loh,M.L., Grupp,S.A., Teachey,D.T. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012; 120(-17-):3510-3518. >>> Ruxolitinib; Dimethylacetamide; propylene glycol; SC; Mice (NSG); 3-4 weeks; Control animals received mp w/ vehicle; animal info (NOD SCID, nonobese); ruxolitinib also known as INCB018424; stress/adverse effects "One ruxolitinib-treated mouse... experienced a wound dehiscence at the subcutaneous pump surgical site" pg 3512; cancer (leukemia); chemotherapeutic.

Q2184 Mittapalli,R.K., Vaidhyanathan,S., Sane,R., Elmquist,W.F. Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032). Journal of Pharmacology and Experimental Therapeutics 2012; 342(-1-):33-40. >>> Vemurafenib; DMSO; propylene glycol; saline; IP; Mice; 48 hours; Animal info (wt, Mdr1a/b -/-, Bcrp1 -/-); infusion rate of 1 ul/hr; wound clips used; brain tissue distribution; cancer (breast); vemurafenib also known as PLX4032; 40% DMSO used; chemotherapeutic.

Q1928 Wang,T.L., Agarwal,S., Elmquist,W.F. Brain Distribution of Cediranib Is Limited by Active Efflux at the Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics 2012; 341(-2-):386-395. >>> Cediranib; DMSO; IP; Mice; 1003D; 72 hours; Animal info (wt, Mdr1a/b -/-, Bcrp1 -/-, and Mdr1a/b -/-, Bcrp1 -/-); cancer (glioma); enzyme inhibitor (tyrosine kinase); chemotherapeutic.

Q1785 Albertsson,P., Lennernaes,B., Norrby,K. Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 2012; 120(-2-):147-156. >>> Irinotecan; mitoxantrone; Saline; SC; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (Sprague Dawley, adult); chemotherapeutic;.

Q1745 Balasis,M.E., Forinash,K.D., Chen,Y.A., Fulp,W.J., Coppola,D., Hamilton,A.D., Cheng,J.Q., Sebti,S.M. Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice. Clinical Cancer Research 2011; 17(-9-):2852-2862. >>> Tipifarnib; Cyclodextrin, 2-hydroxypropyl-beta; DMSO; Mice; 2002; 14 days; Animal info (MMTV/neu); 20% cyclodextrin used; enzyme inhibitor (farnesyltransferase); cancer (breast); chemotherapeutic.

Q1442 Agarwal,S., Sane,R., Ohlfest,J.R., Elmquist,W.F. The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain. Journal of Pharmacology and Experimental Therapeutics 2011; 336(-1-):223-233. >>> Sorafenib; DMSO; IP; Mice; 1003D; 48 hours; Animal info (FVB wild-type, Mdr1a/b -/-, Bcrp1 -/-, Mdr1a/b -/-, Bcrp1 -/-); half-life pg 226 "Sorafenib half-life in plasma and brain after an intravenous dose was determined to be 1.6 and 0.9 h, respectively. Therefore an infusion lasting 48 h was considered to be sufficiently long to attain steady state in both plasma and brain."; good methods, pg 226 "In the intraperitoneal infusion studies, the apparent plasma clearance (CLapp) was calculated by using the equation, CLapp = k0/Css, where, k(0) is the rate of infusion into the peritoneal cavity normalized to body weight (ng/h/kg), and Css is the plasma concentration at steady state (ng/ml)."; enzyme inhibitor (biaryl-urea RAF kinase); cancer (glioma); chemotherapeutic.

Q1219 Martiniova,L., Lu,J., Chiang,J., Bernardo,M., Lonser,R., Zhuang,Z.P., Pacak,K. Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. PLoS One 2011; 6(-2-):U67-U74. >>> LB1; PBS; IP; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; animal info (female, athymic, NCr-nu, 6-10 wks old); cancer; enzyme inhibitor (serine/threonine protein phosphatase 2A, PP2A); chemotherapeutic.

Q0956 Agarwal,S, Sane,R, Gallardo,J.L., Ohlfest,J.R., Elmquist,W.F. Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux. Journal of Pharmacology and Experimental Therapeutics 2010; 334(-1-):147-155. >>> Gefitnib; DMSO; IP; Mice; 1003D; 24, 48 hours; Animal info (wt, Mdr1a/b -/- Bcrp1 -/-, ); dose-response (Table 1); half-life (p.149) "1 hour in mice"; wound clips used; chemotherapeutic.

Q0921 Hinkle,R.T., Lefever,F.R., Dolan,E.T., Reichart,D.L., Zwolshen,J.M., Oneill,T.P., Maloney,K.G., Mattson,J.P., Ferreira,L.F., Musch,T.I., Poole,D.C., Isfort,R.J. Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals. BMC MUSCULOSKELETAL DISORDERS 2011; 12(-;-):U1-U12. >>> PG-873637; Saline, physiological; SC; Rat; 1, 3, 5 months; Controls received mp w/ vehicle; animal info (F344, female, 24 mo old, myocardial infarction); long-term study; pumps replaced every 28 days; PG873637 is a CRF2R selective agonist; 28-day pumps used; new agent; chemotherapeutic.

Q0773 Cuevas,P., Carceller,F., Angulo,J., Gonzalez-Corrochano,R., Cuevas-Bourdier,A., Gimenez-Gallego,G. Antiglioma effects of a new, low molecular mass, inhibitor of fibroblast growth factor. Neuroscience Letters 2011; 491(-1-):1-7. >>> Dobesilate; PBS; CSF/CNS (intratumoral); Rat; 2004; 27 days; Controls received mp w/ vehicle; cancer (glioma); Compound, also known as (2,5-dihydroxyphenyl-sulfonate or 2,5DHPS) is an FGF inhibitor; chemotherapeutic.

Q0715 Shibata,M.A., Morimoto,J., Shibata,E., Kurose,H., Akamatsu,K., Li,Z.L., Kusakabe,M., Ohmichi,M., Otsuki,Y. Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer. BMC CANCER 2010; 10(-;-):U1-U14. >>> Raloxifene; DMSO; ethanol; SC; Mice; 2002; 6 weeks; Animal info (female, 6 wks old, BALB/c); long-term study; pumps replaced every other week; cancer (metastatic breast cancer); stress/adverse reaction: "one animal died from an overdose of anesthesia when the osmotic mini-pumps were changed" (see pg. 7 of 14); raloxifene is a novel selective estrogen receptor modulator; chemotherapeutic.

Q0673 Roland,C.L., Lynn,K.D., Toombs,J.E., Dineen,S.P., Udugamasooriya,D.G., Brekken,R.A. Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer. PLoS One 2009; 4(-11-):U41-U53. >>> GU81; IP; Mice (NOD/SCID); 1, 3, 4 weeks; Controls received IP IgG injection; animal info (6-8 wks old, female, NOD/SCID, BALB/c); cancer (breast); chemotherapeutic.

Q0664 Argiles,J.M., Fontes-Oliveira,C.C., Fuster,G., Ametller,E., Figueras,M., Olivan,M., Lopez-Soriano,F.J., Qu,X.Y., Demuth,J., Stevens,P., Varbanov,A., Wang,F., Isfort,R.J., Busquets,S. PATTERNS OF GENE EXPRESSION IN MUSCLE AND FAT IN TUMOR-BEARING RATS: EFFECTS OF CRF2R AGONIST ON CACHEXIA. Muscle&Nerve 2010; 42(-6-):936-949. >>> PG-873637; SC; Rat; ; Controls received mp w/ NaCl; animal info (male, Wistar, 5 wks old); cancer; PG-873637 is a CRF2R agonist; chemotherapeutic.

Q0602 Beauparlant,P., Bedard,D., Bernier,C., Chan,H., Gilbert,K., Goulet,D., Gratton,M.O., Lavoie,M., Roulston,A., Turcotte,E., Watson,M. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anti-cancer Drugs 2009; 20(-5-):346-354. >>> GMX1777; NaCl; IV (jugular); Mice (nude; SCID); 2001D; 24 hours; Controls received mp w/ vehicle; animal info (BalbC nude, CB17, SCID/SCID, female); comparison of 72 h infusion pump vs 24 h mp; cancer (refractory solid tumors and lymphomas); "The 24 h infusion was the most effective administration schedule identified in mouse xenograft models" pg 352-353; cancer; chemotherapeutic.

Q0584 Lynn,K.D., Udugamasooriya,D.G., Roland,C.L., Castrillon,D.H., Kodadek,T.J., Brekken,R.A. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC CANCER 2010; 10(-;-):U1-U13. >>> GU81; IP; Mice (transgenic); 19 days; Animal info (MMTV-PyMT/Fvb tg, 6 wks old); possibly Model 2004 used (100 ul in 19 days = 0.22 ul/hr); cancer (breast); GU81 is a VEGFR2 antagonist peptoid; chemotherapeutic.

Q0501 Donawho,C.K., Luo,Y., Luo,Y.P., Penning,T.D., Bauch,J.L., Bouska,J.J., Bontcheva-Diaz,V.D., Cox,B.F., DeWeese,T.L., Dillehay,L.E., Ferguson,D.C., Ghoreishi-Haack,N.S., Grimm,D.R., Guan,R., Han,E.K., Holley-Shanks,R.R., Hristov,B., Idler,K.B., Jarvis,K., Johnson,E.F., Kleinberg,L.R., Klinghofer,V., Lasko,L.M., Liu,X.S., Marsh,K.C., McGonigal,T.P., Meulbroek,J.A., Olson,A.M., Palma,J.P., Rodriguez,L.E., Shi,Y., Stavropoulos,J.A., Tsurutani,A.C., Zhu,G.D., Rosenberg,S.H., Giranda,V.L., Frost,D.J. ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical Cancer Research 2007; 13(-9-):2728-2737. >>> ABT-888; Saline; SC; Mice (nude; SCID); 2002; 14 days; Controls received mp w/ vehicle; dose-response (pg 2732, fig. 2); cancer; animal info (C57BL/6, SCID); chemotherapeutic; "ABT-888 administered... via (minipump) not only potentiated cyclophosphamide... but also caused tumor regression, whereas the cyclophosphamide monotherapy only slightly delayed tumor growth." pg 2733.

Q0420 Peng,S.C., Lai,Y.T., Huang,H.Y., Huang,H.D., Huang,Y.S. A novel role of CPEB3 in regulating EGFR gene transcription via association with Stat5b in neurons. NUCLEIC ACIDS RESEARCH 2010; 38(-21-):7446-7457. >>> Endothelial growth factor, recomb.; gefitnib; DMSO; CSF, artificial; BSA; CSF/CNS; Mice; 1004; 14 days; Controls received mp w/ vehicle; animal info (8 wks old, male, C57BL/6J); behavioral testing (Morris water maze test); gefitinib is a chemotherapeutic.

Q00306 Norrby,K., Nordenhem,A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010; 118(-12-):949-957. >>> Dalteparin; epirubicin; Saline; SC; Rat; 2002; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (adult, male, Sprague-Dawley, 6-7 wks old, 218-223 g.); cancer; multiple pumps per animal (2); dalteparin is a low-molecular-weight heparin; epirubicin is a chemotherapeutic.

Q00104 Hoksch,B., Rufer,B., Gazdhar,A., Bilici,M., Beshay,M., Gugger,M., Schmid,R.A. Taurolidine in the prevention and therapy of lung metastases. European Journal of Cardio-thoracic Surgery 2009; 36(-6-):1058-1063. >>> Taurolidine; IV; Rat; 7 days; Controls received tumorial implantation w/o mp; animal info (275-380 g, bdix); 2ML sized pump used; chemotherapeutic.

P9917 Murray,B.W., Guo,C.X., Piraino,J., Westwick,J.K., Zhang,C., Lamerdin,J., Dagostino,E., Knighton,D., Loi,C.M., Zager,M., Kraynov,E., Popoff,I., Christensen,J.G., Martinez,R., Kephart,S.E., Marakovits,J., Karlicek,S., Bergqvist,S., Smeal,T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010; 107(-20-):9446-9451. >>> PF-3758309; Mice (nude); 9 days; Dose response; enzyme inhibitor (P21-activated kinsase); animal info (athymic, CRL breed, 6-8 weeks); cancer; chemotherapeutic.

P9597 Beauvais,D.M., Ell,B.J., McWhorter,A.R., Rapraeger,A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. Journal of Experimental Medicine 2009; 206(-3-):691-705. >>> Synstatin (82-130); synstatin (94-119); synstatin (92-119); cyclic RGDfv; cyclic RADfv; PBS; DMSO; H2O, double distilled; Mice (nude); 2004; 4 weeks; Controls received mp w/vehicle, or PBS; cancer; peptides; animal info (6-8 wks old, female, athymic, BALB/c); 50% DMSO used; chemotherapeutic.

P9572 Restall,C., Doherty,J., Bin Liu,H., Genovese,R., Paiman,L., Byron,K.A., Anderson,R.L., Dear,A.E. A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. International Journal of Cancer 2009; 125(-2-):483-487. >>> Metacept 1; DMSO; cremophor; saline; SC; Mice; 26 days; Half-life (p.483) 20 min.; cancer (breast); animal info (female BALB/c); enzyme inhibitor (histone deacetylase); chemotherapeutic.

P9538 Kazi,A., Carie,A., Blaskovich,M.A., Bucher,C., Van,Thai, Moulder,S., Peng,H., Carrico,D., Pusateri,E., Pledger,W.J., Berndt,N., Hamilton,A., Sebti,S.M. Blockade of Protein Geranylgeranylation Inhibits Cdk2-Dependent p27Kip1 Phosphorylation on Thr187 and Accumulates p27Kip1 in the Nucleus: Implications for Breast Cancer Therapy. MOLECULAR AND CELLULAR BIOLOGY 2009; 29(-8-):2254-2263. >>> GGTI-2418; Polyethylene glycol; DMSO; SC; Mice (nude); 14 days; Controls received mp w/vehicle; cancer (breast); 20% DMSO used; enzyme inhibitor (geranylgeranyltransferase I); chemotherapeutic.

P9278 Nasr,R., Guillemin,M.C., Ferhi,O., Soilihi,H., Peres,L., Berthier,C., Rousselot,P., Robledo-Sarmiento,M., Lallemand-Breitenbach,V., Gourmel,B., Vitoux,D., Pandolfi,P.P., Rochette-Egly,C., Zhu,J., The,H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine 2008; 14(-12-):1333-1342. >>> Bortezomib; cyclic AMP; H89; SC; Mice (nude); mice (transgenic); 1, 3, 6, 7 days; Controls received no treatment; enzyme inhibitor (PKA); cancer (acute promyelocytic leukemia); animal info (nude, PLZF-RARA-RARA-PLZF; PML-RARA5873A Tg); Bortezomib is a proteasom inhibitor; chemotherapeutic;.

P8287 Manabe,T., Okino,H., Maeyama,R., Mizumoto,K., Tanaka,M., Matsuda,T. New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: Potential use for suppression of local recurrence of pancreatic cancer. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS 2005; 73B(-1-):203-207. >>> Gemcitabine; SC; Mice (nude); 1007D; 7 days; Tissue perfusion (intratumoral); comparison of IP injections; cancer (pancreatic); animal info (five week old); pump used as part of a novel infusion device; pictures of device p. 205; PE tubing used to connect pump to perfusion device; continuous infusion resulted in macroscopically undetectable tumors after day 6; chemotherapeutic;.

P8159 Bihorel,S., Camenisch,G., Gross,G., Lemaire,M., Scherrmann,J.M. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metabolism and Disposition 2006; 34(-12-):1945-1949. >>> Imatinib mesylate; hydroxyurea; Saline; SC; Rat; 2ML2; 7, 14 days; Half-life (p. 1948) hydroxyurea<1 hour in rats; enzyme inhibitor (ribonucleotide reductase); cancer (glioblastoma); animal info (Hanover Wistar, 270-310 grams); ATP competitive inhibitor; A.K.A, Gleevec or STI571; chemotherapeutic.

P7931 Yurimoto,S., Miyakawa,A., Okuzawa,A., Sakamoto,S., Sakamoto,K., Hosoda,S., Kamano,T. Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model. Anti-cancer Drugs 2005; 16(-10-):1109-1114. >>> Fluorouracil, 5-; IP; Mice; 1007D; 8 days; Cancer (sarcoma-180); animal info (six week old, male, 30 grams); tumor cells in abdomen; chemotherapeutic.

P7697 Stoeltzing,O., Liu,W., Reinmuth,N., Fan,F., Parry,G.C., Parikh,A.A., McCarty,M.F., Bucana,C.D., Mazar,A.P., Ellis,L.M. Inhibition of integrin alpha beta 1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int.J.Cancer 2003/4/20; 104(-4-):496-503. >>> Fluorouracil, 5-; Saline; IP; Mice; 2002; 2 weeks; Controls received mp w/ vehicle; cancer; angiogenesis; "In preliminary studies..., we observed severe side effects with 5-FU...biweekly injections...thus, we chose to deliver 5-FU by continuous infusion...to minimize toxicity. Additionally, studies have demonstrated an increased efficacy of chemotherapeutic agents when administered continuously." (p. 497).

P6470 Ohtsukasa,S., Okabe,S., Yamashita,H., Iwai,T., Sugihara,K. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. Journal of Cancer Research and Clinical Oncology 2003; 129(-12-):719-726. >>> CDDP; fluorouracil, 5-; IP; Mice; 1007D; 14 days; Controls received mp w/ saline; pumps replaced after 7 days; cancer (colorectal); CDDP (Cisdiamminedichloroplatinum II); is a chemotherapeutic agent.

P6394 Sudoh,M., Kishimoto,Y., Marumoto,B., Inoue,M., Sano,A., Miura,N., Horie,Y., Hasegawa,J., Ryoke,K. A new animal model of continuous catheterization for investigating mechanisms of arteritis associated with chemotherapy. LIFE SCIENCES 2004; 74(-24-):3025-3032. >>> Fluorouracil, 5-FU; peplomycin; Saline, heparinized; IA (abdominal aorta); Rat; 2ML1; 7 days; Controls received mp w/ vehicle; cancer; chemotherapeutic agents; PE-10 and 60 used; tubing attached using a moment binding agent (alon-alfa); catheter schematic p. 3027; pump placed IP.

P6260 Gibbs,R.B., Gabor,R., Cox,T., Johnson,D.A. Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat. Psychoneuroendocrinology 2004; 29(-6-):741-748. >>> Raloxifene; Estradiol, 17B-; DMSO; cyclodextrin, hydroxypropyl-beta (molecusol); SC; Rat; 2004; ; Controls received mp w/ vehicle; replacement therapy (ovariectomy); pumps replaced every 28 days; 20% cyclodextrin&1% DMSO used; incorrectly states pumping rate as 2.5 ul/hr; behavioral study; research diets; chemotherapeutic.

P5213 Peng,D., Qian,C., Sun,Y., Barajas,M.A., Prieto,J. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno- associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol. 2000/6; 32(-6-):975-985. >>> Etoposide; IP; Rat; 1 week; Functionality of mp verified by measuring etoposide concentration in tumor tissue; cancer; etoposide (VP-16) is a chemotherapeutic agent.

P5136 Morales,C., Zurita,M., Vaquero,J. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. Journal of Neuro-oncology 2002; 56(--):219-226. >>> Irinotecan (CPT-11); Saline; IP; rat; 2004; 28 days; functionality of mp verified by residual content; comparison of IP and intratumoral injections vs. mp; no stress (see p. 222): animals tolerated the pumps: no infections or peritoneal fibrosis were observed; cancer; enzyme inhibitor (topoisomerase I); animals with pumps showed less toxicity: "schedules of continuous administration of CPT-11 were more efficacious and less toxic..." (p. 223); chemotherapeutic;.

P3566 Veerman,G., Ruiz van Haperen,V.W.T., Vermorken,J.B., Noordhuis,P., Braakhuis,B.J.M., Pinedo,H.M., Peters,G.J. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother.Pharmacol. 1996; (--):335-342. >>> Gemcitabine; SC; Mice; 1003D; 1007D; 3, 7 days; Functionality of mp verified by in vitro testing; comparison of ip and bench-mounted infusion pump injections vs. mp; half-life (p. 1996); cancer; toxicology; "...prolonged infusion of gemcitabine can give a better antitumor activity than bolus injections and shows promise of being active in clinical trials." (p. 335); 2',2'-difluorodeoxycytidine is gemcitabine; chemotherapeutic;.

top of page

25. Paclitaxel

16295 Cadamuro, M., Spagnuolo, G., Sambado, L., Indraccolo, S., Nardo, G., Rosato, A., Brivio, S., Caslini, C., Stecca, T., Massani, M., Bassi, N., Novelli, E., Spirli, C., Fabris, L., Strazzabosco, M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Res 2016; 76(-16-):4775-84. >>> Paclitaxel; Cremophor EL, Ethanol; IP; Mice (SCID); 1004; Controls received mp w/ vehicle; animal info (SCID mice 6–8 weeks old); functionality of mp verified by bioluminescence imaging to check metastatic spread; 50% Cremophor, 50% ethanol used; cancer (Cholangiocarcinoma); Xenograft model; Dose (2.6 mg/kg/d);.

12836 Zhou, Z.L., Zhang, H., Jin, A.M., Min, S.X., Yu, B., Chen, Y.H. A combination of taxol infusion and human umbilical cord mesenchymal stem cells transplantation for the treatment of rat spinal cord injury. Brain Research 2012; 1481(-;-):79-89. >>> Paclitaxel; Ethanol; cremophor EL; CSF/CNS (intrathecal); Rat; 2004; Control animals received mp w/ PBS; animal info (Sprague Dawley, female, 200-250 g); Paclitaxel also known as Taxol; 50% ethanol used; 50% cremophor EL used; spinal cord injury.

12669 Serizawa, K., Yogo, K., Aizawa, K., Tashiro, Y., Takahari, Y., Sekine, K., Suzuki, T., Ishizuka, N., Ishida, H. Paclitaxel-Induced Endothelial Dysfunction in Living Rats Is Prevented by Nicorandil via Reduction of Oxidative Stress. JOURNAL OF PHARMACOLOGICAL SCIENCES 2012; 119(-4-):349-358. >>> Paclitaxel; DMSO; cremophor EL; water, distilled; SC; Rat; mice; 2ML1; 1007D; Control animals received mp w/ vehicle; animal info (Sprague Dawley, male, 250-300; ICR, male, 10-11 wks old); post op. care (bupivacaine); 50% DMSO used; 25% Cremophor EL used.

top of page

26. TIMP

P5373 Takahashi,M., Fukami,S., Iwata,N., Inoue,K., Itohara,S., Itoh,H., Haraoka,J., Saido,T.C. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacological Research 2002; 46(-2-):155-163. >>> TIMP-1; TIMP-2; PBS; CSF/CNS (intratumoral); Rat; 2002; 3, 7, or 14 days; Controls received mp w/ vehicle; tissue perfusion (tumor); functionality of mp verified by immunohistochemistry of agents; cancer; enzyme inhibitor; ALZET brain infusion kit used; MMP inhibitors (tissue inhibitors of metalloprotease = TIMP); rat glioma model.

top of page

27. Timp

5504 Takahashi, M., Fukami, S., Iwata, N., Inoue, K., Itohara, S., Itoh, H., Haraoka, J., Saido, T.C. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacological Research 2002; 46(-2-):155-163. >>> TIMP-1; TIMP-2; PBS; CSF/CNS (intratumoral); Rat; 2002; Controls received mp w/ vehicle; tissue perfusion (tumor); functionality of mp verified by immunohistochemistry of agents; cancer; enzyme inhibitor; ALZET brain infusion kit used; MMP inhibitors (tissue inhibitors of metalloprotease = TIMP); rat glioma model.

top of page

28. Topotecan

13291 Lin, F., Marchetti, S., Pluim, D., Iusuf, D., Mazzanti, R., Schellens, J.H.M., Beijnen, J.H., van Tellingen, O. Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues. Clinical Cancer Research 2013; 19(-8-):2084-2095. >>> Topotecan; Glucose; SC; Mice; 1003D; Animal info (WT, Abcg2-/-, Abcb1a/b-/-, Abcc4-/-, 8-14 wks old); Camptothecins brain distribution (Fig. 5).

12498 Aljuffali, I.A., Mock, J.N., Costyn, L.J., Nguyen, H., Nagy, T., Cummings, B.S., Arnold, R.D. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. CANCER BIOLOGY&THERAPY 2011; 12(-5-):407-420. >>> Topotecan; Saline; SC; Mice (nude); Controls received mp w/ vehicle; animal info (NCr, male); cancer (prostate).

12152 Huang, H.S., Allen, J.A., Mabb, A.M., King, I.F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, JW Jr, Lee, H.M., Chen, X., Jin, J., Bridges, A.S., Zylka, M.J., Roth, B.L., Philpot, B.D. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2012; 481(-7380-):185-U90. >>> Topotecan; Tartaric acid; saline; CSF/CNS; Mice; 2001; 2002; Animal info (Ube3a m+/pYfP); cyanoacrylate adhesive used; schematic of cannula insertion (Fig 3a).

top of page

29. Vinblastine

9011 Albertsson, P., Lennernaes, B., Norrby, K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncologica 2008; 47(-2-):293-300. >>> Vinblastine sulfate; Saline, physiological; SC; Rat; 2001; 2ML1; Controls received mp w/ vehicle; dose-response (fig. 2); no stress (see pg. 296); cancer; animal info (male, Sprague Dawley, 217-219g.).

8801 Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P., Kerbel, R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation 2000; 105(-8-):15-24. >>> Vinblastine sulfate; Saline; SC; Mice (SCID); Controls received IP injections; comparison of IP injections vs. mp; no stress (see pg. R19); cancer (neuroblastoma); toxicology; animal info (SCID, 4-6 weeks old, 15-20 grams); IP bolus given at start of mp treatment.

top of page

30. Vincristine

13817 Jarvis, M.F., Scott, V.E., McGaraughty, S., Chu, K.L., Xu, J., Niforatos, W., Milicic, I., Joshi, S., Zhang, Q.W., Xia, Z.R., Jarvis, M.F. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochemical Pharmacology 2014; 89(--):536-544. >>> Vincristine sulfate; IV (jugular); Rat; 2002; Animal info (male, Sprague Dawley, 200-420g); behavioral testing (paw withdrawal); pumps primes overnight; used PE-60 catheter tubing; chemotherapy-induced neuropathic pain model;.

13582 Yang, Y., Zhang, Y.G., Lin, G.A., Xie, H.Q., Pan, H.T., Huang, B.Q., Liu, J.D., Liu, H., Zhang, N., Li, L., Chen, J.H. Spinal Changes of a Newly Isolated Neuropeptide Endomorphin-2 Concomitant with Vincristine-Induced Allodynia. PLoS One 2014; 9(-2-):U627-U638. >>> Vincristine; IV (jugular); Rat; 2002; Control animals received mp w/ saline; animal info (adult, male, Sprague Dawley, 200 g).

13389 Ji, X.T., Qian, N.S., Zhang, T., Li, J.M., Li, X.K., Wang, P., Zhao, D.S., Huang, G., Zhang, L., Fei, Z., Jia, D., Niu, L. Spinal Astrocytic Activation Contributes to Mechanical Allodynia in a Rat Chemotherapy-Induced Neuropathic Pain Model. PLoS One 2013; 8(-4-):U440-U451. >>> Vincristine; Saline; IV (jugular); Rat; 2002; Controls received mp w/ vehicle; animal info (male, adult, sprague dawley, 200g); behavioral testing (Rotarod test, Von Frey monofilaments, Hargreaves'method);"Implantation of the mini-osmotic pump is a simple procedure with the advantages of performing only once, providing reliable intravenous drug delivery, taking little time to perform, and good tolerance"pg 9; Used to induce chemotherapy-induced neuropathic pain in rat model.

top of page

31. Other

13202 Dudek, A.Z., Raza, A., Chi, M., Singhal, M., Oberoi, R., Mittapalli, R.K., Agarwal, S., Elmquist, W.F. Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer 2013; 11(-2-):155-160. >>> Sorafenib; sunitinib; DMSO; saline; IP; 1003D; Animal info (Friend virus B-type (FVB) wild type, and Abcb1a/b knockout mice); cancer (renal carcinoma and brain metastases); cancer; enzyme inhibitor (tyrosine kinase); chemotherapeutic.

12862 Agarwal, S., Manchanda, P., Vogelbaum, M.A., Ohlfest, J.R., Elmquist, W.F. Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma. Drug Metabolism and Disposition 2013; 41(-1-):33-39. >>> Erlotinib; DMSO; IP; Mice; 1003D; Animal info (Mdr1ab -/-, Bcrp1 -/-, 8-10 wks old); wound clips used; half-life ("approximately 1 hour") pg 34; cancer (glioma);"Erlotinib half-life in mice has been reported to be approximately 1 hour (Marchetti et al., 2008), so an infusion lasting 48 hours was considered to be sufficient to attain steady state in both the brain and plasma."pg 34; chemotherapeutic.

12861 Li, L., Agarwal, S., Elmquist, W.F. Brain Efflux Index To Investigate the Influence of Active Efflux on Brain Distribution of Pemetrexed and Methotrexate. Drug Metabolism and Disposition 2013; 41(-3-):659-667. >>> Pemetrexed; IP; Mice; 1003D; animal info (C57BL/6, male, Bcrp 1 -/-); post op. care (ibuprofen in the drinking water); pemetrexed is an antifolate; chemotherapeutic;.

top of page

Looking for references? We can help!

Since 1977, scientist around the world have used ALZET pumps to conduct their research, publishing their results in high-impact journals. The ALZET bibliography now contains over 16,000 publications! We can perform a custom search for references relevant to your research.

Request your ALZET bibliography search!

 

Order the ALZET SurgicalImplantation Video

What researchers are saying ...

“Insofar as multiple dosing is concerned, we propose that only administration by pump (or administration more than four times a day) can provide clinical-like occupancies for haloperidol, olanzapine, and risperidone.” Kapur et al., The Journal of Pharmacology and Experimental Therapeutics 2003;305:625-631.